Edition:
United States

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

8.03USD
27 Apr 2017
Change (% chg)

-- (--)
Prev Close
$8.03
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
140,539
52-wk High
$9.69
52-wk Low
$3.11

Latest Key Developments (Source: Significant Developments)

Tetraphase Pharmaceuticals completes enrollment of ignite4 phase 3 clinical trial of eravacycline in complicated intra-abdominal infections
Monday, 3 Apr 2017 08:00am EDT 

Tetraphase Pharmaceuticals Inc : Tetraphase Pharmaceuticals completes enrollment of ignite4 phase 3 clinical trial of eravacycline in complicated intra-abdominal infections .Tetraphase Pharmaceuticals Inc says expects to report top-line data from ignite4 phase 3 clinical trial in Q3 of 2017.  Full Article

Tetraphase pharma Q4 loss per share $0.61
Wednesday, 8 Mar 2017 04:05pm EST 

Tetraphase Pharmaceuticals Inc : Tetraphase Pharmaceuticals reports fourth quarter and full-year 2016 financial results and highlights key 2017 milestones . Q4 loss per share $0.61 . Q4 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S . Q4 revenue $1.1 million versus I/B/E/S view $1.4 million .Tetraphase Pharmaceuticals Inc - as of December 31, 2016, Tetraphase had cash and cash equivalents of $142.1 million and 36.9 million shares outstanding.  Full Article

Tetraphase Pharmaceuticals reports Q3 loss per share $0.58
Thursday, 3 Nov 2016 04:30pm EDT 

Tetraphase Pharmaceuticals Inc - : Tetraphase Pharmaceuticals reports third quarter 2016 financial results and reviews recent progress . Q3 loss per share $0.58 . Q3 revenue $900,000 versus $2.9 million . Q3 revenue view $1.6 million -- Thomson Reuters I/B/E/S .Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Tetraphase pharmaceuticals doses first patient in IGNITE4 phase 3 clinical trial of Eravacycline in cIAI
Friday, 14 Oct 2016 07:30am EDT 

Tetraphase Pharmaceuticals Inc : Tetraphase Pharmaceuticals doses first patient in IGNITE4 phase 3 clinical trial of eravacycline in cIAI . Tetraphase Pharmaceuticals Inc - top-line IGNITE4 data expected in 4Q 2017 .Tetraphase Pharmaceuticals Inc- study is expected to enroll approximately 450 adult patients.  Full Article

Tetraphase Pharmaceuticals reports Q2 loss per share $0.47
Thursday, 4 Aug 2016 04:52pm EDT 

Tetraphase Pharmaceuticals Inc : Q2 loss per share $0.47 . Q2 revenue view $2.1 million -- Thomson Reuters I/B/E/S . Tetraphase pharmaceuticals reports second quarter 2016 financial results and highlights recent progress . Q2 revenue $1.2 million versus $3.3 million . Q2 earnings per share view $-0.46 -- Thomson Reuters I/B/E/S .Cash, cash equivalents, expected revenue from u.s. Government awards, will be sufficient to fund operations into middle of 2018.  Full Article

More From Around the Web

BRIEF-Tetraphase Pharmaceuticals completes enrollment of ignite4 phase 3 clinical trial of eravacycline in complicated intra-abdominal infections

* Tetraphase Pharmaceuticals completes enrollment of ignite4 phase 3 clinical trial of eravacycline in complicated intra-abdominal infections